Thurston Springer Miller Herd & Titak Inc. Takes Position in Catalent, Inc. (NYSE:CTLT)

Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Catalent, Inc. (NYSE:CTLT) during the second quarter, Holdings Channel reports. The institutional investor acquired 750 shares of the company’s stock, valued at approximately $42,000.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Catalent by 1.1% in the first quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company’s stock valued at $1,151,872,000 after purchasing an additional 218,682 shares during the last quarter. Capital World Investors boosted its holdings in Catalent by 6.1% in the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock valued at $857,264,000 after purchasing an additional 1,098,474 shares during the last quarter. Nomura Holdings Inc. boosted its holdings in Catalent by 149.4% in the fourth quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock valued at $516,126,000 after purchasing an additional 6,881,914 shares during the last quarter. Cadian Capital Management LP boosted its holdings in Catalent by 14.3% in the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after purchasing an additional 759,600 shares during the last quarter. Finally, Capital International Investors boosted its holdings in Catalent by 1.2% in the fourth quarter. Capital International Investors now owns 2,994,467 shares of the company’s stock valued at $134,541,000 after purchasing an additional 34,856 shares during the last quarter.

Catalent Price Performance

Shares of CTLT traded up $0.41 during mid-day trading on Tuesday, hitting $59.56. 1,590,661 shares of the company were exchanged, compared to its average volume of 2,218,511. Catalent, Inc. has a 1-year low of $31.80 and a 1-year high of $60.20. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51. The company has a 50 day moving average of $56.66 and a 200-day moving average of $56.12. The stock has a market cap of $10.78 billion, a price-to-earnings ratio of -9.69, a price-to-earnings-growth ratio of 2.47 and a beta of 1.16.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). The business had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. Analysts expect that Catalent, Inc. will post -0.17 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on CTLT shares. Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 target price on shares of Catalent in a research note on Thursday, July 11th. Barclays increased their target price on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, June 28th. Finally, StockNews.com started coverage on shares of Catalent in a research note on Thursday, August 1st. They set a “sell” rating on the stock. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $55.65.

Insider Buying and Selling at Catalent

In other news, CEO Alessandro Maselli sold 9,088 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the sale, the chief executive officer now owns 177,521 shares in the company, valued at approximately $10,431,133.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the transaction, the chief executive officer now owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ricky Hopson sold 662 shares of the firm’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the completion of the sale, the insider now owns 29,974 shares in the company, valued at $1,785,251.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,810 shares of company stock worth $858,941. Insiders own 0.31% of the company’s stock.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.